Abstract
Introduction Sarcopenia is a heterogeneous skeletal muscle disorder involving the loss of muscle mass and function. However, the prevalence of sarcopenia based on the most recent definition remains to be determined in older people with chronic airway diseases.
Objective To evaluate sarcopenia prevalence and association with chronic airway diseases and its lung function in an older population, using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria.
Methods We performed a cross-sectional analysis in 5082 participants (mean age, 69.0±8.8 years, 56% females) from the Rotterdam Study. Participants with interpretable spirometry and an available assessment of sarcopenia were included. The appendicular skeletal muscle mass index (ASMI) and handgrip strength (HGS) were assessed using dual-energy X-ray absorptiometry (DXA) and a hydraulic hand dynamometer, respectively. We analysed the association between sarcopenia and chronic airway diseases by using regression models adjusted for age, sex, smoking status, total fat percentage and other relevant confounders.
Results Participants with chronic airway diseases had higher prevalence of probable sarcopenia (12.0%, 95% CI 10.2; 13.8) and confirmed sarcopenia (3.0%, 95% CI 2.1; 3.9) than without. Chronic airway diseases were associated with “probable sarcopenia” (OR=1.28, 95%CI 1.02, 1.60), “confirmed sarcopenia” (OR=2.13, 95%CI 1.33, 3.43), reduced HGS (β=−0.51 [−0.90; −0.11]) and reduced ASMI (β=−0.19 [−0.25; −0.14]). FEV1<80% was associated with lower HGS (β=−1.03 [−1.75; −0.31]) and lower ASMI (β=−0.25 [−0.36; −0.15]) than FEV1≥80%.
Conclusion Sarcopenia was prevalent and associated with chronic airway diseases among older population. These results suggest the need for early diagnosis of sarcopenia in older people with chronic airway diseases by applying EWGSOP2 recommendations.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Benz has nothing to disclose.
Conflict of interest: Dr. Trajanoska has nothing to disclose.
Conflict of interest: Dr. Schoufour has nothing to disclose.
Conflict of interest: Dr. Lahousse reports awards sponsored by AstraZeneca and Chiesi and expert consultation for Boehringer Ingelheim GmbH and Novartis, outside the submitted work.
Conflict of interest: Dr. de Roos has nothing to disclose.
Conflict of interest: Dr. Terzikhan has nothing to disclose.
Conflict of interest: Dr. Medina-Gomez has nothing to disclose.
Conflict of interest: KV works for a research group who received/receives research grants from Yamanouchi, Pfizer/BI, Novartis, GSK none of which are related to the content of this work.
Conflict of interest: Dr. Williams has nothing to disclose.
Conflict of interest: Dr. Stricker has nothing to disclose.
Conflict of interest: Dr. Franco has nothing to disclose.
Conflict of interest: Dr. Ikram has nothing to disclose.
Conflict of interest: Dr. Rivadeneira has nothing to disclose.
Conflict of interest: Dr. Brusselle has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received August 13, 2020.
- Accepted September 28, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.